LOMBARDO, ANGELO LEONE
 Distribuzione geografica
Continente #
AS - Asia 1.285
NA - Nord America 1.208
EU - Europa 637
SA - Sud America 252
AF - Africa 25
OC - Oceania 2
Totale 3.409
Nazione #
US - Stati Uniti d'America 1.146
SG - Singapore 498
CN - Cina 403
BR - Brasile 212
HK - Hong Kong 206
SE - Svezia 197
IT - Italia 110
DE - Germania 82
VN - Vietnam 67
RU - Federazione Russa 52
GB - Regno Unito 48
CA - Canada 37
PL - Polonia 22
FI - Finlandia 21
IN - India 21
MX - Messico 20
FR - Francia 19
AT - Austria 18
ES - Italia 18
JP - Giappone 18
ZA - Sudafrica 16
BD - Bangladesh 13
IQ - Iraq 12
AR - Argentina 11
NL - Olanda 11
CO - Colombia 10
IE - Irlanda 9
EC - Ecuador 8
LT - Lituania 8
ID - Indonesia 7
PK - Pakistan 7
IR - Iran 6
PT - Portogallo 6
MA - Marocco 5
TR - Turchia 5
CH - Svizzera 4
IL - Israele 4
VE - Venezuela 4
AE - Emirati Arabi Uniti 3
BG - Bulgaria 3
NP - Nepal 3
UA - Ucraina 3
AU - Australia 2
AZ - Azerbaigian 2
EG - Egitto 2
MK - Macedonia 2
PE - Perù 2
PY - Paraguay 2
AM - Armenia 1
BB - Barbados 1
BE - Belgio 1
BH - Bahrain 1
CL - Cile 1
CR - Costa Rica 1
DK - Danimarca 1
DZ - Algeria 1
GY - Guiana 1
KG - Kirghizistan 1
KR - Corea 1
KZ - Kazakistan 1
LB - Libano 1
MY - Malesia 1
NI - Nicaragua 1
PA - Panama 1
RO - Romania 1
RS - Serbia 1
SA - Arabia Saudita 1
TH - Thailandia 1
TN - Tunisia 1
TT - Trinidad e Tobago 1
UY - Uruguay 1
UZ - Uzbekistan 1
Totale 3.409
Città #
Singapore 239
Ashburn 213
Dallas 202
Hong Kong 201
Shanghai 90
New York 89
Beijing 83
Hefei 66
Los Angeles 54
Milan 49
Lawrence 47
Princeton 47
Washington 29
Munich 27
Boardman 23
São Paulo 23
Warsaw 20
Denver 19
Hanoi 19
Ho Chi Minh City 18
Nuremberg 18
Orem 16
Tokyo 16
Brooklyn 15
Montreal 15
Stockholm 15
Moscow 13
The Dalles 13
Atlanta 11
Boston 11
Houston 11
Johannesburg 11
San Francisco 11
Toronto 11
Chennai 10
Guangzhou 10
Helsinki 10
Mexico City 10
Seattle 10
London 9
Poplar 9
Turku 9
Phoenix 8
Baghdad 7
Chicago 7
Council Bluffs 7
Dublin 7
Jiaxing 7
Bogotá 6
Curitiba 6
Frankfurt am Main 6
Haiphong 6
Hangzhou 6
Rio de Janeiro 6
Santa Clara 6
Shenzhen 6
Vienna 6
Amsterdam 5
Falkenstein 5
Manchester 5
Monza 5
Barcelona 4
Belo Horizonte 4
Charlotte 4
Columbus 4
Lannion 4
Ottawa 4
Reston 4
Rishon LeTsiyyon 4
Salvador 4
Xi'an 4
Zhengzhou 4
Ankara 3
Annapolis 3
Aveiro 3
Berlin 3
Biggleswade 3
Bologna 3
Caraguatatuba 3
Dhaka 3
Ferrara 3
Franca 3
Lyon 3
Manassas 3
Mumbai 3
Noisy-le-Sec 3
Nova Iguaçu 3
Novara 3
Rome 3
San Jose 3
Sofia 3
Assago 2
Baku 2
Bauru 2
Cairo 2
Campo 2
Cape Town 2
Capão da Canoa 2
Chapel Hill 2
City of London 2
Totale 2.058
Nome #
Laboratory-Scale Lentiviral Vector Production and Purification for Enhanced Ex Vivo and In Vivo Genetic Engineering 95
In Vitro Selection of Engineered Transcriptional Repressors for Targeted Epigenetic Silencing 94
Erratum: IL-10-Engineered Human CD4+ Tr1 Cells Eliminate Myeloid Leukemia in an HLA Class I-Dependent Mechanism (Molecular Therapy (2017) 25(10) (2254–2269), (S1525001617303143), (10.1016/j.ymthe.2017.06.029)) 82
Permanent Epigenetic Gene Silencing 81
miR-126 identifies a quiescent and chemo-resistant human B-ALL cell subset that correlates with minimal residual disease 81
Efficient gene delivery and targeted expression to hepatocytes in vivo by improved lentiviral vectors 80
Genome editing: a tool for research and therapy: Targeted genome editing hits the clinic 77
SELECTION BY MEANS OF ARTIFICIAL TRANSACTIVATORS 76
An unbiased genome-wide analysis of zinc-finger nuclease specificity 76
Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer 76
A microRNA-regulated lentiviral vector mediates stable correction of hemophilia B mice 75
Gene Modification and Three-Dimensional Scaffolds as Novel Tools to Allow the Use of Postnatal Thymic Epithelial Cells for Thymus Regeneration Approaches 74
DNA damage contributes to neurotoxic inflammation in Aicardi-Goutières syndrome astrocytes 69
COMPOSITIONS AND METHODS FOR EPIGENETIC REGULATION OF HBV GENE EXPRESSION 69
T-cell defects in patients with ARPC1B germline mutations account for combined immunodeficiency 69
CRISPR/CAS9-BASED GENOME EDITING TO MODEL THE ANTI-LEUKEMIA IMMUNE RESPONSE AND IDENTIFY ITS MOLECULAR PLAYERS 66
GENE SILENCING 66
Lentiviral correction of enzymatic activity restrains macrophage inflammation in adenosine deaminase 2 deficiency 65
Engineering of immune checkpoints B7-H3 and CD155 enhances immune compatibility of MHC-I-/- iPSCs for β cell replacement 62
TRPML1 links lysosomal calcium to autophagosome biogenesis through the activation of the CaMKKβ/VPS34 pathway 61
Altered Cl− homeostasis hinders forebrain GABAergic interneuron migration in a mouse model of intellectual disability 58
Epigenome-editing strategies to enhance oligodendroglial differentiation from human induced pluripotent stem cells 57
NY-ESO-1 TCR single edited stem and central memory T cells to treat multiple myeloma without graft-versus-host disease 57
iPSC-derived neural precursors exert a neuroprotective role in immune-mediated demyelination via the secretion of LIF 55
Inheritable Silencing of Endogenous Genes by Hit-and-Run Targeted Epigenetic Editing 55
Delivery methods and compositions for nuclease-mediated genome engineering in hematopoietic stem cells 54
Editing Human Lymphocyte Specificity for Safe and Effective Adoptive Immunotherapy of Leukemia 54
Editing Human Lymphocyte Specificity for Safe and Effective Adoptive Immunotherapy of Leukemia 54
VECTOR PRODUCTION 53
Durable and efficient gene silencing in vivo by hit-and-run epigenome editing 52
Editing Human Lymphocyte Specificity for Safe and Effective Adoptive Immunotherapy of Leukemia 52
Galectin-3 in Prostate Cancer Stem-Like Cells Is Immunosuppressive and Drives Early Metastasis 52
Site-specific integration and tailoring of cassette design for sustainable gene transfer 51
From TCR Gene Transfer to TCR Gene Editing of Central Memory T Lymphocytes for Immunotherapy of Leukemia 50
IL-10-Engineered Human CD4+ Tr1 Cells Eliminate Myeloid Leukemia in an HLA Class I-Dependent Mechanism 48
Methods and compositions for targeted integration 48
Targeted gene addition in human epithelial stem cells by zinc-finger nuclease-mediated homologous recombination. 47
Genome editing for scalable production of alloantigen-free lentiviral vectors for in vivo gene therapy 47
Gene therapy for a mucopolysaccharidosis type I murine model with lentiviral-IDUA vector 46
Targeting Integration to Selected Genomic Loci and In Situ Tailoring of Cassette Design Allows Robust Transgene Expression without Perturbing Endogenous Transcription 46
Limited transgene immune response and long-term expression of human alpha-L-iduronidase in young adult mice with mucopolysaccharidosis type I by liver-directed gene therapy 46
In vitro gene therapy of mucopolysaccharidosis type I by lentiviral vectors 45
Targeting lentiviral vector expression to hepatocytes limits transgene-specific immune response and establishes long-term expression of human antihemophilic factor IX in mice 45
Deletion of a pseudogene within a fragile site triggers the oncogenic expression of the mitotic CCSER1 gene 45
Genomic instability in induced stem cells 44
Gene editing in human stem cells using zinc finger nucleases and integrase-defective lentiviral vector delivery 43
Targeted genome editing in human repopulating haematopoietic stem cells 42
Preclinical modeling highlights the therapeutic potential of hematopoietic stem cell gene editing for correction of SCID-X1 42
Engineering of NK activating receptor ligands enhances immune compatibility of MHC-I-/- iPSC for cell therapy of type 1 diabetes 41
Therapeutic gene editing in CD34+ hematopoietic progenitors from Fanconi anemia patients. 41
Reversible immortalisation enables genetic correction of human muscle progenitors and engineering of next-generation human artificial chromosomes for Duchenne muscular dystrophy 41
Use of critical care resources during the first 2 weeks (February 24–March 8, 2020) of the Covid-19 outbreak in Italy 41
Lipo-Xenopeptide Polyplexes for CRISPR/Cas9 based Gene editing at ultra-low dose 39
Engineering of NK activating receptor ligands enhances immune compatibility of MHC-I-/- iPSC-derived β cells for cell therapy of type 1 diabetes 39
Loss of transcriptional control over endogenous retroelements during reprogramming to pluripotency 38
Leukocytes recruited by tumor-derived HMGB1 sustain peritoneal carcinomatosis 38
TCR gene editing results in effective immunotherapy of leukaemia without the development of GvHD 38
Targeted gene correction in osteopetrotic-induced pluripotent stem cells for the generation of functional osteoclasts 38
Lentiviral gene transfer and ex vivo expansion of human primitive stem cells capable of primary, secondary, and tertiary multilineage repopulation in NOD/SCID mice 37
T Cell Receptor Gene Transfer into Naive and Central Memory Lymphocytes by Lentiviral Vectors for a Safe and Effective Adoptive Immune Therapy of Leukemia 36
Trattamento chirurgico della fibrillazione atriale associata a valvulopatia mitralica. “Maze Procedure” e chirurgia della mitrale. 35
Targeted gene therapy and cell reprogramming in Fanconi anemia 34
The first reported generation of several induced pluripotent stem cell lines from homozygous and heterozygous Huntington's disease patients demonstrates mutation related enhanced lysosomal activity 34
The immune response to lentiviral-delivered transgene is modulated in vivo by transgene expressing antigen presenting cells but not by CD4+CD25+ regulatory T cells 32
NY-ESO-1 Single Edited T Cells to Treat Multiple Myeloma without Inducing GvHD 32
Patient-Specific iPSC-Derived Endothelial Cells Provide Long-Term Phenotypic Correction of Hemophilia A 29
A potent epigenetic editor targeting human PCSK9 for durable reduction of low-density lipoprotein cholesterol levels 14
Totale 3.559
Categoria #
all - tutte 23.780
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 23.780


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202111 0 0 0 0 0 8 3 0 0 0 0 0
2021/202232 0 0 0 19 2 0 5 0 3 0 0 3
2022/2023293 101 76 24 3 2 42 8 23 6 2 6 0
2023/2024348 2 15 38 59 41 99 4 21 2 11 16 40
2024/20251.156 93 16 29 79 74 106 196 114 183 82 86 98
2025/20261.630 262 242 221 481 363 61 0 0 0 0 0 0
Totale 3.559